Cidara Therapeutics Inc.

CDTX | NASDAQ

Price Alert Chart Builder DCF Calculator

$221.38

$0 (0.00%)

At close: Jan 8, 2026, 9:30 AM ET

Overview Rating Statistics Financials Earnings Analysts Ownership Profile

Market Data

Market Cap $5.61B

Enterprise Value $5.32B

Beta 1.53

Average Volume 1.35M

Shares Outstanding (Diluted) 15.55M

Shares Change YoY 138.09%

Institutional Ownership N/A

Exchange NASDAQ

ISIN US1717572069

Price Performance

Price Change 1M 0.7%

Price Change 3M 90.6%

Price Change 6M 300.2%

Price Change YTD 0.2%

Price Change 1Y 822.4%

Price Change 3Y N/A

Price Change 5Y 371.0%

1M CAGR (ann.) 0.5%

1Y CAGR (ann.) 725.7%

5Y CAGR (ann.) 40.8%

All-Time CAGR -3.4%

Valuation

PE Ratio -18.79

Forward PE N/A

PEG Ratio -1.17

Forward PEG -24.33

PS Ratio N/A

Forward PS 479.70

PB Ratio 13.29

P/FCF Ratio -42.23

P/Adj. FCF Ratio -39.40

P/OCF Ratio -33.24

EV/Sales N/A

EV/EBIT -28.00

EV/EBITDA -28.03

EV/FCF -40.03

Earnings Yield -5.3%

FCF Yield -2.4%

Adj. FCF Yield -2.5%

Financial Health

Net Cash $291.67M

Total Debt $1.98M

Cash & Short-Term Investments $293.65M

Total Assets $518.65M

Current Ratio 4.62

Quick Ratio 4.62

Debt / Equity Ratio 0.00

Debt / EBITDA -0.01

Debt / FCF -0.01

OCF / Debt -67.01

Interest Coverage 0.00

Altman Z-Score 32.58

Piotroski F-Score 3

Margins & Profitability

Gross Profit Margin 0.0%

Operating Profit Margin 0.0%

EBITDA Margin 0.0%

Net Profit Margin 0.0%

FCF Margin N/A

Adj. FCF Margin N/A

SBC / Revenue 0.0%

SBC Impact (per share) -7.2%

Returns

Return on Assets -25.5%

Return on Equity -37.3%

Return on Invested Capital -33.3%

Return on Capital Employed -33.4%

Return on Tangible Assets -25.5%

Historical Growth (CAGR)

Revenue CAGR 3Y -109.3%

Revenue CAGR 5Y -38.0%

Revenue CAGR 10Y 16.1%

EPS CAGR 3Y -13.7%

EPS CAGR 5Y 2.9%

EPS CAGR 10Y 19.7%

FCF CAGR 3Y -47.1%

FCF CAGR 5Y -49.0%

FCF CAGR 10Y -15.0%

Analyst Forecasts

Analyst Rating Buy

Analyst Count 11

EPS Growth Next 3Y 52.1%

Revenue Growth Next 3Y N/A

Earnings Date Nov 5, 2025

EPS Estimate (next Q) -$1.34

EPS Growth Est (next Q) -43.7%

Revenue Est (next Q) N/A

Revenue Growth Est (next Q) N/A

Fair Value Estimates

Graham Number N/A

Graham Upside N/A

Lynch Fair Value N/A

Lynch Upside N/A

Price Target $177.88

Price Target Upside -19.6%

Cash Flow

Operating Cash Flow $-132.94M

Free Cash Flow $-132.94M

Adj. Free Cash Flow $-142.47M

FCF Per Share -$6.66

OCF Per Share -$6.66

OCF/S Ratio 0.0%

Income Statement

Revenue $0

Gross Profit $-45M

Operating Income $-195.46M

EBITDA $-189.91M

Net Income $-184.74M

EPS (Diluted) -$11.78

Revenue / Employee N/A

Profit / Employee $-4.86M

Employees 38